Logo image of PTGX

PROTAGONIST THERAPEUTICS INC (PTGX) Stock Fundamental Analysis

NASDAQ:PTGX - Nasdaq - US74366E1029 - Common Stock - Currency: USD

38.75  +0.26 (+0.68%)

After market: 38.75 0 (0%)

Fundamental Rating

6

Taking everything into account, PTGX scores 6 out of 10 in our fundamental rating. PTGX was compared to 572 industry peers in the Biotechnology industry. While PTGX has a great health rating, its profitability is only average at the moment. PTGX is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

PTGX had positive earnings in the past year.
PTGX had a positive operating cash flow in the past year.
PTGX had negative earnings in each of the past 5 years.
PTGX had a negative operating cash flow in each of the past 5 years.
PTGX Yearly Net Income VS EBIT VS OCF VS FCFPTGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M -80M -100M

1.2 Ratios

PTGX has a Return On Assets of 28.29%. This is amongst the best in the industry. PTGX outperforms 99.11% of its industry peers.
Looking at the Return On Equity, with a value of 32.12%, PTGX belongs to the top of the industry, outperforming 98.58% of the companies in the same industry.
PTGX has a Return On Invested Capital of 21.06%. This is amongst the best in the industry. PTGX outperforms 98.40% of its industry peers.
Industry RankSector Rank
ROA 28.29%
ROE 32.12%
ROIC 21.06%
ROA(3y)-36.52%
ROA(5y)-35.95%
ROE(3y)-41.46%
ROE(5y)-48.91%
ROIC(3y)N/A
ROIC(5y)N/A
PTGX Yearly ROA, ROE, ROICPTGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

With an excellent Profit Margin value of 52.76%, PTGX belongs to the best of the industry, outperforming 99.29% of the companies in the same industry.
The Operating Margin of PTGX (46.05%) is better than 99.64% of its industry peers.
Industry RankSector Rank
OM 46.05%
PM (TTM) 52.76%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PTGX Yearly Profit, Operating, Gross MarginsPTGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10K -20K -30K

More info and screens

9

2. Health

2.1 Basic Checks

PTGX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for PTGX has been increased compared to 1 year ago.
PTGX has more shares outstanding than it did 5 years ago.
PTGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PTGX Yearly Shares OutstandingPTGX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
PTGX Yearly Total Debt VS Total AssetsPTGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

An Altman-Z score of 20.38 indicates that PTGX is not in any danger for bankruptcy at the moment.
The Altman-Z score of PTGX (20.38) is better than 93.43% of its industry peers.
There is no outstanding debt for PTGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 20.38
ROIC/WACC2.23
WACC9.44%
PTGX Yearly LT Debt VS Equity VS FCFPTGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

PTGX has a Current Ratio of 10.70. This indicates that PTGX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PTGX (10.70) is better than 82.06% of its industry peers.
PTGX has a Quick Ratio of 10.70. This indicates that PTGX is financially healthy and has no problem in meeting its short term obligations.
PTGX has a Quick ratio of 10.70. This is amongst the best in the industry. PTGX outperforms 82.06% of its industry peers.
Industry RankSector Rank
Current Ratio 10.7
Quick Ratio 10.7
PTGX Yearly Current Assets VS Current LiabilitesPTGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 201.53% over the past year.
Looking at the last year, PTGX shows a very strong growth in Revenue. The Revenue has grown by 125.73%.
Measured over the past years, PTGX shows a quite strong growth in Revenue. The Revenue has been growing by 14.17% on average per year.
EPS 1Y (TTM)201.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.9%
Revenue 1Y (TTM)125.73%
Revenue growth 3Y27.97%
Revenue growth 5Y14.17%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, PTGX will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.79% on average per year.
The Revenue is expected to grow by 49.67% on average over the next years. This is a very strong growth
EPS Next Y282.62%
EPS Next 2Y0.48%
EPS Next 3Y-10.6%
EPS Next 5Y19.79%
Revenue Next Year701.96%
Revenue Next 2Y87.46%
Revenue Next 3Y43%
Revenue Next 5Y49.67%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PTGX Yearly Revenue VS EstimatesPTGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
PTGX Yearly EPS VS EstimatesPTGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 14.57 indicates a correct valuation of PTGX.
96.80% of the companies in the same industry are more expensive than PTGX, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 29.63. PTGX is valued rather cheaply when compared to this.
The Forward Price/Earnings Ratio is negative for PTGX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 14.57
Fwd PE N/A
PTGX Price Earnings VS Forward Price EarningsPTGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PTGX is valued cheaply inside the industry as 97.87% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, PTGX is valued cheaply inside the industry as 98.22% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 10.08
EV/EBITDA 10.02
PTGX Per share dataPTGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

PTGX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PTGX's earnings are expected to decrease with -10.60% in the coming years. This may justify a cheaper valuation.
PEG (NY)0.05
PEG (5Y)N/A
EPS Next 2Y0.48%
EPS Next 3Y-10.6%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PTGX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROTAGONIST THERAPEUTICS INC

NASDAQ:PTGX (2/21/2025, 8:00:01 PM)

After market: 38.75 0 (0%)

38.75

+0.26 (+0.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-18 2025-03-18/amc
Inst Owners106.3%
Inst Owner Change-96.69%
Ins Owners1.46%
Ins Owner Change-1.55%
Market Cap2.31B
Analysts83.75
Price Target60.18 (55.3%)
Short Float %6.62%
Short Ratio6.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.69%
Min EPS beat(2)12.85%
Max EPS beat(2)18.53%
EPS beat(4)4
Avg EPS beat(4)399.61%
Min EPS beat(4)12.85%
Max EPS beat(4)1399.31%
EPS beat(8)6
Avg EPS beat(8)202.14%
EPS beat(12)10
Avg EPS beat(12)141.03%
EPS beat(16)12
Avg EPS beat(16)104.67%
Revenue beat(2)1
Avg Revenue beat(2)36.16%
Min Revenue beat(2)-48.93%
Max Revenue beat(2)121.25%
Revenue beat(4)3
Avg Revenue beat(4)56.92%
Min Revenue beat(4)-48.93%
Max Revenue beat(4)121.25%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.61%
PT rev (3m)11.92%
EPS NQ rev (1m)468.25%
EPS NQ rev (3m)350.13%
EPS NY rev (1m)7.42%
EPS NY rev (3m)34.85%
Revenue NQ rev (1m)33.93%
Revenue NQ rev (3m)29.73%
Revenue NY rev (1m)0.79%
Revenue NY rev (3m)9.74%
Valuation
Industry RankSector Rank
PE 14.57
Fwd PE N/A
P/S 7.13
P/FCF 10.08
P/OCF 10.03
P/B 4.34
P/tB 4.34
EV/EBITDA 10.02
EPS(TTM)2.66
EY6.86%
EPS(NY)-1.48
Fwd EYN/A
FCF(TTM)3.85
FCFY9.93%
OCF(TTM)3.86
OCFY9.97%
SpS5.43
BVpS8.92
TBVpS8.92
PEG (NY)0.05
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 28.29%
ROE 32.12%
ROCE 26.66%
ROIC 21.06%
ROICexc 130.08%
ROICexgc 130.08%
OM 46.05%
PM (TTM) 52.76%
GM N/A
FCFM 70.79%
ROA(3y)-36.52%
ROA(5y)-35.95%
ROE(3y)-41.46%
ROE(5y)-48.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 111.41%
Cap/Sales 0.33%
Interest Coverage 250
Cash Conversion 153.46%
Profit Quality 134.17%
Current Ratio 10.7
Quick Ratio 10.7
Altman-Z 20.38
F-Score7
WACC9.44%
ROIC/WACC2.23
Cap/Depr(3y)91.94%
Cap/Depr(5y)94.77%
Cap/Sales(3y)2.68%
Cap/Sales(5y)86.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)201.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.9%
EPS Next Y282.62%
EPS Next 2Y0.48%
EPS Next 3Y-10.6%
EPS Next 5Y19.79%
Revenue 1Y (TTM)125.73%
Revenue growth 3Y27.97%
Revenue growth 5Y14.17%
Sales Q2Q%N/A
Revenue Next Year701.96%
Revenue Next 2Y87.46%
Revenue Next 3Y43%
Revenue Next 5Y49.67%
EBIT growth 1Y197.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year240.42%
EBIT Next 3Y32.73%
EBIT Next 5YN/A
FCF growth 1Y319.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y322.64%
OCF growth 3YN/A
OCF growth 5YN/A